Phase 3 Trial of New Oral Drug for Pulmonary Arterial Hypertension: Ralinepag Reduces Risk of Clinical Worsening by 55%
A trial involving 687 participants showed that once-daily ralinepag can delay disease worsening and improve measures of cardiac stress and walking distance; however, the high discontinuation rate and the exclusion of some trial data from China remain key points of regulatory review.